Home / Brands / Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Recalls
165 recalls on record · August 8, 2012 to December 17, 2025 · Drugs
Recalls by year
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
November 10, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ezetimibe and Simvastatin Tablets, 10 mg/40 mg, a) 30 count (NDC 43598-743-30), b) 90 count (NDC 43598-743-9
Hazard: Failed Excipient Specifications; product manufactured using an excipient found to be OOS for conductivity
November 10, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ezetimibe and Simvastatin Tablets, 10 mg/80 mg, a) 30 count (NDC 43598-745-30), b) 90 count (NDC 43598-745-9
Hazard: Failed Excipient Specifications; product manufactured using an excipient found to be OOS for conductivity
November 10, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ezetimibe and Simvastatin Tablets, 10 mg/20 mg, a) 30 count (NDC 43598-744-30), b) 90 count (NDC 43598-744-9
Hazard: Failed Excipient Specifications; product manufactured using an excipient found to be OOS for conductivity
November 10, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, a) 90 count (NDC 43598-742-90) and b) 1000 count (NDC 43598-
Hazard: Failed Excipient Specifications; product manufactured using an excipient found to be OOS for conductivity
October 27, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Omeprazole Delayed-Release Capsules, 20 mg* (equivalent to 20.6 mg omeprazole magnesium), 24 Hour, 14-count capsules pe
Hazard: CGMP Deviations: Customer complaint for the presence of a staple co-mingled with capsules within the bottle.
August 25, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Tizanidine HCl Tablets, USP 4 mg, 150-count bottles, Rx only, Mfd By: Dr. Reddy's Laboratories limited, Srikakulam Distr
Hazard: Failed Tablet/Capsule Specification: Some tablets are shaved
June 23, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Atorvastatin Calcium Tablets, USP 10 mg, 500-count bottles, Rx Only, Dr. Reddy's Mfd. By: Dr. Reddy's Laboratories Limit
Hazard: Failed Impurities/Degradation Specifications: due to presence of ATV cyclo IP and FP impurities
June 2, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Atorvastatin Calcium Tablets, USP 10 mg*, Rx Only, 500 count bottle, Mfd By: Dr. Reddy's Laboratories Limited, Bachupall
Hazard: Failed Impurities -Degradation Specifications:due to presence of ATV cyclo IP and FP impurities
March 10, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Progesterone Capsules, 200 mg, 100-count bottles, Rx Only, MADE IN FRANCE; Distributed by: Dr. Reddy's Laboratories, Inc
Hazard: Failed Dissolution Specifications: Out-of-specification results observed for dissolution during stability testing.
March 10, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Atorvastatin Calcium Tablets, 40mg, packaged in a) 90-count bottles, NDC 55111-123-90; b) 500-count bottles, NDC 55111-
Hazard: Failed Impurities/Degradation Specifications:presence of ATV cyclo IP and FP, Dihydroxy epoxy and Dieto epoxy impurities
March 3, 2021DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Imatinib Mesylate Tablets 100mg, packaged as a) 90-count bottles (NDC 43598-344-90); and b) For Institutional Use Only 3
Hazard: Failed Dissolution Specifications
May 6, 2020DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Esomeprazole Magnesium Delayed Release Capsules USP, 40 mg*, 1000-count bottles, Rx only, Mfd. By: Dr. Reddy's Laborato
Hazard: Discoloration: product contains brown pellets
April 8, 2020DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Phytonadione Injectable Emulsion, USP, 10 mg/mL 1 mL ampule (NDC 43598-405-11) packaged in 25 x 1 mL Single-Dose Ampules
Hazard: Defective Container: Recall is due to breaking and shattering of ampules upon opening
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 63868-480-24), b.) 50-count bottles (NDC 63868-480-50) (CDMA)
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 75 mg, a.) 30- count bottles (NDC 0363-0131-30), b.) 80-count bottles (NDC 0363-0131-80) (Walgr
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ranitidine Tablets, USP 150 mg, 24 count bottles, NDC 55111-404-34 (OTC)
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ranitidine Tablets, USP 75 mg, 60 count bottles, NDC 55111-131-60, (OTC)
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Dr. Reddy's Ranitidine Capsules, USP 300 mg, a.) 30 count bottles (NDC 55111-130-30) b.) 100 count bottles (NDC 55111-13
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, 40 count bottles, NDC 11673-849-40 (Target) OTC.
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 75 mg, NDC 57896-715 (GeriCare) OTC.
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 71713-203-02), b.)95 count bottles (NDC 71713-203-05) (Thirty
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, a.) 95 count bottles (NDC 43598-808-62), b.) 220 count bottles (NDC 43598-808-65) (HCA)
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets 75 mg, a.) 30 count bottles (NDC 63868-482-30), 60 count bottles (NDC 63868-482-60) (CDMA) OTC
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 75 mg 30 count bottles (NDC 30142-131-30) (Kroger)
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 75 mg, a.) 30 count bottles (NDC 69842-871-30) b.) 80 count bottles (NDC 69842-871-80) c.)160 c
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 30142-505-34), b.) 50 count bottles (NDC 30142-505-50) (Kroger
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, a.) 65 count bottles (NDC 49035-404-61) b.) 130 count bottles (NDC 49035-404-13) c.) 220
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 0363-0010-34), b.) 65 count bottles (NDC 0363-0010-61) , c.) 9
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.
November 13, 2019DrugsFDA
Dr. Reddy's Laboratories, Inc. recalls Ranitidine Tablets, USP 150 mg, 190 count bottles (2x95) Tray (Sam's Club) OTC, NDC 150062076 UPC Code 078742089720
Hazard: CGMP Deviations: Presence of NDMA impurity detected in product.